abstract |
The invention relates to glucopyranosyloxypyrazole derivatives or their pharmaceutically acceptable salts exhibiting human SGLT2 inhibitory activity and useful as agents for the prevention or treatment of diabetes, diabetic complications or obesity. The invention also relates to pharmaceutical compositions comprising said derivatives as well as to their intermediates. The derivatives are represented by the general formula in which R1 represents a hydrogen atom or a lower alkyl group; one of Q1 and T1 represents a group of the formula while the other is a lower alkyl group or a halo (lower alkyl) group; R2 is a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo (lower alkyl) group or a halogen atom. |